Opportunity-first subsidiary creation
Each subsidiary houses one to three drug development programs selected for unmet need, scientific rationale, and licensing attractiveness.
UK-based biopharma venture studio
AI-powered company creation for licensable drug assets.
Three Lions BioCapital creates and invests in subsidiaries developing novel drugs for truly unmet medical needs, with each program designed from inception around pharmaceutical licensing potential.
Key features
Venture studio model
Wholly owned subsidiaries with focused development programs.
Licensing-led design
Programs evaluated around pharma partner fit, stage, and exit value.
AI-enabled sourcing
Proprietary intelligence framework built to surface white-space opportunities.
Built for the pharmaceutical innovation gap.
Patent cliffs, declining R&D productivity, and a constrained IPO market are increasing demand for externally developed, licensable drug candidates. Three Lions is structured around that demand.
Pharma licensing as the organizing principle
Indication selection, candidate sourcing, diligence, and partner engagement are evaluated through a commercial licensing lens.
Capital-efficient shared platform
Centralized services and active portfolio management reduce duplicated overhead, directing more capital toward impactful development work.
WHISE directs attention where the market has not yet converged.
WHISE, the firm's proprietary white space intelligence search engine, is an agentic AI framework that interrogates overlapping disease, target, and specialist provider datasets to identify underexploited opportunities.
Repeatable opportunity discovery
Structured rubrics help surface licensing-attractive programs at a speed and scale beyond a manual business development network alone.
Tiered investment signals
Recommendations such as PURSUE initiate focused diligence, from rapid AI-assisted dossiers to expert and counterparty engagement.
Mandate flexibility
No fixed therapeutic area, modality, stage, or geography prevents the fund from following the strongest available opportunities.
UK operating advantages
A UK base provides access to internationally recognized development pathways and potential R&D tax credit benefits that may reduce effective program costs.
Investor materials and inquiries.
For the current Tearsheet or a conversation about the Three Lions BioCapital strategy, please contact us directly.